GGrantIndex
← Leaderboards

Punita Dhawan

University Of Nebraska Medical Center

$3,662,344
Attributed
$4,679,160
Total exposure
7
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $786.9K · FY200625
$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$4,679,160 · 4
VA$0 · 3

By mechanism

R01$4,091,640 · 2
R21$587,520 · 2
I01$0 · 2
IK6$0 · 1

Top collaborators

Most similar at University Of Nebraska Medical Center

Same institution · by research overlap

Others in their field

Top investigators on “Malignant Neoplasms

Research focus

Malignant NeoplasmsProteinsMouse ModelClaudin-1 ProteinColon CarcinomaNeoplasm MetastasisTumorColorectal CancerMediatingMolecularCancer CellSignal TransductionCessation Of LifeInvestigationTight JunctionsResistanceRegulationDiagnostic Neoplasm StagingDiagnosisSamplingLaboratoriesCellsToxic EffectMetastatic Colorectal

Grant awards (32)

Novel Tools for Colon Cancer Detection and Therapy$0
I01 · FY2025 · VA · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2025 · VA · contact PI
Impact of CLDN1 inhibition on chemoresistance and metastasis of colon cancer$474,168
R01 · FY2024 · CA · contact PI
Impact of CLDN1 inhibition on chemoresistance and metastasis of colon cancer$213,771
R01 · FY2024 · CA · contact PI
Impact of CLDN1 inhibition on chemoresistance and metastasis of colon cancer$1
R01 · FY2024 · CA · contact PI
Novel Tools for Colon Cancer Detection and Therapy$0
I01 · FY2024 · VA · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2024 · VA · contact PI
Impact of CLDN1 inhibition on chemoresistance and metastasis of colon cancer$548,542
R01 · FY2023 · CA · contact PI
Impact of CLDN1 inhibition on chemoresistance and metastasis of colon cancer$238,397
R01 · FY2023 · CA · contact PI
Novel Tools for Colon Cancer Detection and Therapy$0
I01 · FY2023 · VA · contact PI
Impact of CLDN1 inhibition on chemoresistance and metastasis of colon cancer$461,779
R01 · FY2022 · CA · contact PI
Role of claudin-1 in Colon Cancer$0
I01 · FY2022 · VA · contact PI
Impact of CLDN1 inhibition on chemoresistance and metastasis of colon cancer$571,142
R01 · FY2021 · CA · contact PI
Role of claudin-1 in Colon Cancer$0
I01 · FY2021 · VA · contact PI
Role of claudin-1 in Colon Cancer$0
I01 · FY2020 · VA · contact PI
Mastl, a novel therapeutic target in Colon Cancer$193,042
R21 · FY2019 · CA · contact PI
Role of claudin-1 in Colon Cancer$0
I01 · FY2019 · VA · contact PI
Mastl, a novel therapeutic target in Colon Cancer$165,391
R21 · FY2018 · CA · contact PI
Role of Claudin-1 in Colon Cancer$0
I01 · FY2016 · VA · contact PI
Role of Claudin-1 in Colon Cancer$0
I01 · FY2015 · VA · contact PI
Role of Claudin-1 in Colon Cancer$0
I01 · FY2015 · VA · contact PI
Role of Claudin-1 in Colon Cancer$0
I01 · FY2014 · VA · contact PI
Role of Claudin-1 in Colon Cancer$0
I01 · FY2013 · VA · contact PI
Regulation of Claudin-1 mediated Colon Tumor Progression and Metastasis$334,058
R01 · FY2011 · CA · contact PI
Regulation of Claudin-1 mediated Colon Tumor Progression and Metastasis$51,157
R01 · FY2011 · CA · contact PI
Regulation of Claudin-1 mediated Colon Tumor Progression and Metastasis$291,650
R01 · FY2010 · CA · contact PI
Regulation of Claudin-1 mediated Colon Tumor Progression and Metastasis$44,293
R01 · FY2010 · CA · contact PI
Regulation of Claudin-1 mediated Colon Tumor Progression and Metastasis$291,650
R01 · FY2009 · CA · contact PI
Regulation of Claudin-1 mediated Colon Tumor Progression and Metastasis$291,650
R01 · FY2008 · CA · contact PI
Regulation of Claudin-1 mediated Colon Tumor Progression and Metastasis$279,382
R01 · FY2007 · CA · contact PI
Role of claudin-1 in colon tumor progression and metastasis$113,124
R21 · FY2007 · CA · contact PI
Role of claudin-1 in colon tumor progression and metastasis$115,963
R21 · FY2006 · CA · contact PI